Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Lemaitre Vascular Q3 2026 Results: Net Income $15M, Down 13.5% YoY

LeMaitre Vascular reported net sales of $68.0 million for Q3 2026, a 11% increase over the prior year, though net income decreased to $15.0 million from $17.4 million. For the nine months ended September 30, 2026, the company saw improved profitability with net income rising to $47.8 million compared to $42.2 million in the same period of 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue68.061.0
Gross profit48.746.0
Profit before tax19.722.6
Net income15.017.4
EPS (diluted, $ a share)$0.65$0.75

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-13.5%
Revenue, year on year+11.3%
Gross margin71.7%
Operating margin26.0%
Source

10-Q filed with the SEC, NASDAQ: LMAT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Lemaitre Vascular Inc: key numbers

Share price
$77.01Close, Nov 16
Market cap
$1.76B
Shares outstanding
22.88MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Lemaitre Vascular Inc

All →
4:41 PM ET 8-K
Financial Results

Lemaitre Vascular Financial Results

LeMaitre Vascular reported Q3 2026 sales of $68.0 million, an 11% increase driven by strong performance in grafts and shunts. The company also announced the $19.2 million acquisition of vascular assets from B. Braun and declared a quarterly dividend of $0.25 per share.

Term
Q3 2026

“We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft’s international launch and the continued growth of RestoreFlow Allografts. The acquired B. Braun products will strengthen our core vascular portfolio while leveraging our expanding 31-country sales force.”

George LeMaitre, Chairman/CEO
4:11 PM ET 8-K
Leadership Change

Lemaitre Vascular Leadership Change

David B. Roberts notified the company of his intent to retire as President effective December 31, 2026, after 29 years of executive service. Mr. Roberts will continue to serve on the Board of Directors following his retirement as an employee.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.